Literature DB >> 6849825

Recent upper respiratory tract infection and pityriasis rosea: a case-control study of 249 matched pairs.

T Y Chuang, H O Perry, D M Ilstrup, L T Kurland.   

Abstract

A sample of 249 patients was drawn from an original population of 939 patients with pityriasis rosea identified in an earlier population-based study of pityriasis rosea in Rochester, Minnesota. A control was selected for each case, matched for age, sex, and year of diagnosis. Comparison was made with regard to recent immunization, history of atopy, and recent infection. A statistically significant number of patients had experienced recent upper respiratory tract infection (P less than 0.005). The association between recent infection and pityriasis rosea is discussed.

Entities:  

Mesh:

Year:  1983        PMID: 6849825     DOI: 10.1111/j.1365-2133.1983.tb01061.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  4 in total

1.  A Randomized, Double-blind, Placebo-Controlled Study of Efficacy of Oral Acyclovir in the Treatment of Pityriasis Rosea.

Authors:  Satyaki Ganguly
Journal:  J Clin Diagn Res       Date:  2014-05-15

Review 2.  Pityriasis Rosea, Gianotti-Crosti Syndrome, Asymmetric Periflexural Exanthem, Papular-Purpuric Gloves and Socks Syndrome, Eruptive Pseudoangiomatosis, and Eruptive Hypomelanosis: Do Their Epidemiological Data Substantiate Infectious Etiologies?

Authors:  Antonio Chuh; Vijay Zawar; Gabriel F Sciallis; Werner Kempf; Albert Lee
Journal:  Infect Dis Rep       Date:  2016-03-21

Review 3.  Pityriasis rosea in pregnancy: A case series and literature review.

Authors:  Lena Wenger-Oehn; Thomas Graier; Christina Ambros-Rudolph; Robert Müllegger; Christina Bittighofer; Peter Wolf; Angelika Hofer
Journal:  J Dtsch Dermatol Ges       Date:  2022-05-26       Impact factor: 5.231

4.  Study of role of streptococcal throat infection in pityriasis rosea.

Authors:  Madhuri Parija; Devinder Mohan Thappa
Journal:  Indian J Dermatol       Date:  2008       Impact factor: 1.494

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.